Airway inflammation in asthma: Key players beyond the Th2 pathway

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 1, 2016, Pages 46-52

  Jan, Alex Klein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Endothelial cells; Epithelial cells; IL 4; Innate lymphoid cell type 2; Phosphodiesterase

Indexed keywords

CYCLIC AMP; DEOXYRIBOZYME; GLUCOCORTICOID; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; NOTCH RECEPTOR; PHOSPHODIESTERASE; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR GATA 3; CYTOKINE;

ASTHMA; BASOPHIL; CELL ACTIVATION; CYCLIC AMP BLOOD LEVEL; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; INNATE IMMUNITY; LYMPHOID CELL; NONHUMAN; OBESITY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOOTH MUSCLE FIBER; TH2 CELL; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ASTHMA; CYTOKINES; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; TH2 CELLS;

EID: 84948579893     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000224     Document Type: Review

References (76)

1. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19:46-54.
2. Erle DJ, Sheppard D. The cell biology of asthma. J Cell Biol 2014; 205:621-631.
3. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14:536-542.
4. Cheng LE, Sullivan BM, Retana LE, et al. IgE-Activated basophils regulate eosinophil tissue entry by modulating endothelial function. J Exp Med 2015; 212:513-524.
5. Caubet JC, Masilamani M, Rivers NA, et al. Potential non-T cells source of interleukin-4 in food allergy. Pediatr Allergy Immunol 2014; 25:243-249.
6. Sicherer SH, Wood RA, Stablein D, et al. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy. J Allergy Clin Immunol 2010; 125:1077-1083; e1078.
7. Nei Y, Obata-Ninomiya K, Tsutsui H, et al. GATA-1 regulates the generation and function of basophils. Proc Natl Acad Sci U S A 2013; 110:18620-18625.
8. Moqbel R, Ying S, Barkans J, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995; 155:4939-4947.
9. Moller GM, de Jong TA, van der Kwast TH, et al. Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol 1996; 14:439-443.
10. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012; 5:157-176.
11. Doherty TA, Khorram N, Lund S, et al. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol 2013; 132:205-213.
12. Mjosberg J, Bernink J, Golebski K, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012; 37:649-659.
13. Braunstahl GJ, Overbeek SE, Kleinjan A, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107:469-476.
14. KleinJan A, McEuen AR, Dijkstra MD, et al. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000; 106:677-686.
15. Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers 2013; 1:e24333-1-e24333-5.
16. Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol 2009; 9:116-124.
17. Fasnacht N, Huang HY, Koch U, et al. Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses. J Exp Med 2014; 211:2265-2279.
18. Mochizuki K, Xie F, He S, et al. Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol 2013; 190:3772-3782.
19. Pletinckx K, Stijlemans B, Pavlovic V, et al. Similar inflammatory DC maturation signatures induced by TNF or Trypanosoma brucei antigens instruct default Th2-cell responses. Eur J Immunol 2011; 41:3479-3494.
20. Zuiker RGJA, Ruddy MK, Morelli N, et al. Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. Eur Clin Respir Journal 2015; 2:28319.
21. Saglani S, Lui S, Ullmann N, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132:676-685; e613.
22. Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both Dutch and British hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015; 135:63-72.
23. Kleinjan A, Holm AF, Dijkstra MD, et al. Preventive treatment of intranasal fluticasone propionate reduces cytokine mRNA expressing cells before and during a single nasal allergen provocation. Clin Exp Allergy 2000; 30:1476-1485.
24. Nakagome K, Matsushita S, Nagata M. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 2012; 158 (Suppl 1):96-102.
25. Aujla SJ, Alcorn JF. T(H)17 cells in asthma and inflammation. Biochim Biophys Acta 2011; 1810:1066-1079.
26. Willart MA, Hammad H. Alarming dendritic cells for allergic sensitization. Allergol Int 2010; 59:95-103.
27. Willart MA, Deswarte K, Pouliot P, et al. Interleukin-1alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012; 209:1505-1517.
28. Gauvreau GM, OByrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370:2102-2110.
29. Cheng D, Xue Z, Yi L, et al. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med 2014; 190:639-648.
30. Beale J, Jayaraman A, Jackson DJ, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014; 6:256ra134.
31. Andreakos E, Papadopoulos NG. IL-25: the missing link between allergy, viral infection, and asthma? Sci Transl Med 2014; 6:256fs38.
32. Castanhinha S, Sherburn R, Walker S, et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. J Allergy Clin Immunol 2015; 136:312-322.
33. Snelgrove RJ, Gregory LG, Peiro T, et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J Allergy Clin Immunol 2014; 134:583-592; e586.
34. Klein Wolterink RG, Kleinjan A, van Nimwegen M, et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012; 42:1106-1116.
35. Wu J, Liu F, Zhao J, et al. Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway. Cell Biochem Funct 2013; 31:496-503.
36. Morita H, Arae K, Unno H, et al. An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 2015; 43:175-186.
37. Molofsky AB, VanGool F, Liang HE, et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 2015; 43:161-174.
38. Gregory LG, Jones CP, Walker SA, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 2013; 68:82-90.
39. Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 2012; 109:1673-1678.
40. Lefrancais E, Duval A, Mirey E, et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 2014; 111:15502-15507.
41. Homburg U, Renz H, Timmer W, et al. Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with T2-driven asthma. J Allergy Clin Immunol 2015; 136:797-800.
42. Krug N, Hohlfeld JM, Kirsten AM, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015; 372:1987-1995.
43. Charles N, Watford WT, Ramos HL, et al. Lyn kinase controls basophil GATA-3 transcription factor expression and induction of Th2 cell differentiation. Immunity 2009; 30:533-543.
44. Taghon T, Yui MA, Rothenberg EV. Mast cell lineage diversion of T lineage precursors by the essential T cell transcription factor GATA-3. Nat Immunol 2007; 8:845-855.
45. Masuda A, Hashimoto K, Yokoi T, et al. Essential role of GATA transcriptional factors in the activation of mast cells. J Immunol 2007; 178:360-368.
46. Jogie-Brahim S, Min HK, Fukuoka Y, et al. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004; 113:1086-1092.
47. Himes BE, Hunninghake GM, Baurley JW, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009; 84:581-593.
48. Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010; 42:36-44.
49. Ahmad F, Gao G, Wang LM, et al. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells. J Immunol 1999; 162:4864-4875.
50. Lee J, Kim TH, Murray F, et al. Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma. Proc Natl Acad Sci U S A 2015; 112:1529-1534.
51. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderateto-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374:695-703.
52. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013; 1:714-727.
53. Stokes JR. Promising future therapies for asthma. Int Immunopharmacol 2014; 23:373-377.
54. Beute J. Emergency treatment of status asthmaticus with enoximone. Br J Anaesth 2014.
55. Bethke T, Eschenhagen T, Klimkiewicz A, et al. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung 1992; 42:437-445.
56. Armani E, Amari G, Rizzi A, et al. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem 2014; 57:793-816.
57. Villetti G, Carnini C, Battipaglia L, et al. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration-in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. J Pharmacol Exp Ther 2015; 352:568-578.
58. Yarova PL, Stewart AL, Sathish V, et al. Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma. Sci Transl Med 2015; 7:284ra260.
59. Penn RB. Physiology. Calcilytics for asthma relief. Science 2015; 348:398-399.
60. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998; 124:229-237.
61. Wright LC, Seybold J, Robichaud A, et al. Phosphodiesterase expression in human epithelial cells. Am J Physiol 1998; 275:L694-L700.
62. Kobayashi K, Tsubosaka Y, Hori M, et al. Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway. Arterioscler Thromb Vasc Biol 2013; 33:565-571.
63. Noda K, Zhang J, Fukuhara S, et al. Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through alpha-And beta-catenins in cyclic AMP-Epac-Rap1 signal-Activated endothelial cells. Mol Biol Cell 2010; 21:584-596.
64. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-Acting phosphodiesterase 3/4 inhibitors, RPL554 [9, 10-dimethoxy-2(2, 4, 6-trimethylphenylimino)-3-(n-carbamoyl-2-Aminoethyl)-3, 4, 6, 7-tetrahydro-2H-pyrimido[6, 1-A]isoquinolin-4-one] and RPL565 [6, 7-dihydro-2-(2, 6-diisopropylphenoxy)-9, 10-dimethoxy-4H-pyrimido[6, 1-A]isoquino lin-4-one]. J Pharmacol Exp Ther 2006; 318:840-848.
65. Planquois JM, Mottin G, Artola M, et al. Effects of phosphodiesterase inhibitors and salbutamol on microvascular leakage in guinea-pig trachea. Eur J Pharmacol 1998; 344:59-66.
66. Nagai K, Watanabe M, Seto M, et al. Nitric oxide decreases cell surface expression of aquaporin-5 and membrane water permeability in lung epithelial cells. Biochem Biophys Res Commun 2007; 354:579-584.
67. Sidhaye V, Hoffert JD, King LS. cAMP has distinct acute and chronic effects on aquaporin-5 in lung epithelial cells. J Biol Chem 2005; 280:3590-3596.
68. Fanelli V, Puntorieri V, Assenzio B, et al. Pulmonary-derived phosphoinositide 3-kinase gamma (PI3Kgamma) contributes to ventilator-induced lung injury and edema. Intensive Care Med 2010; 36:1935-1945.
69. Mokra D, Drgova A, Pullmann R Sr, Calkovska A. Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury. Pulm Pharmacol Ther 2012; 25:216-222.
70. Suttorp N, Ehreiser P, Hippenstiel S, et al. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 1996; 174:181-194.
71. Van der Mey M, Bommele KM, Boss H, et al. Synthesis and structure-Activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003; 46:2008-2016.
72. Lu Y, Van Bever HP, Lim TK, et al. Obesity, Asthma Prevalence and IL-4: Roles of Inflammatory Cytokines, Adiponectin and Neuropeptide Y. Pediatr Allergy Immunol 2015.
73. van Huisstede A, Rudolphus A, Castro Cabezas M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 2015; 70:659-667.
74. Kim JY, Sohn JH, Lee JH, Park JW. Obesity increases airway hyperresponsiveness via the TNF-Alpha pathway and treating obesity induces recovery. PLoS One 2015; 10:e0116540.
75. Ahangari F, Sood A, Ma B, et al. Chitinase 3-like-1 regulates both visceral fat accumulation and asthma-like Th2 inflammation. Am J Respir Crit Care Med 2015; 191:746-757.
76. van Huisstede A, Rudolphus A, van Schadewijk A, et al. Bronchial and systemic inflammation in morbidly obese subjects with asthma: a biopsy study. Am J Respir Crit Care Med 2014; 190:951-954.